Bluejay Diagnostics completed a private placement raising $8.5 million upfront, with potential additional proceeds of $15.2 million if warrants are fully exercised. The funds will support FDA approval processes, including clinical studies, and general R&D activities. The company expects this financing to extend its cash runway into early 2027, beyond the anticipated FDA submission, and possibly well past FDA approval and commercialization if warrants are exercised. H.C. Wainwright & Co. served as the placement agent for the offering.
At B2Gold Corp's 2026 Annual General and Special Meeting, shareholders voted on key company matters with 63.06% turnout. All ten nominated directors were re-elected with strong support, and resolutions to appoint PricewaterhouseCoopers LLP as auditor...
Jim Rickards highlights a tiny $2 stock holding exclusive rights to a massive $2.7 trillion mineral deposit in the US, containing gold, copper, silver, and critical metals vital for technology and defense. The project has been stalled by environmenta...
Aurion Resources Ltd. shareholders overwhelmingly approved a plan for Agnico Eagle Mines Limited to acquire all outstanding Aurion shares at C$2.60 each. The approval was secured at a special meeting, with over 99% voting in favor. The transaction no...
Anika Therapeutics granted 3,360 restricted stock units (RSUs) to a newly hired non-executive employee on June 1, 2026. This grant was made under the company's 2021 Inducement Plan as a material inducement for accepting employment, in compliance with...
SpaceX has secured a deal with Google to provide computing power at $920 million per month starting October through June 2029, potentially earning SpaceX $30 billion. This deal supports SpaceX's role as a key AI infrastructure provider amid growing d...
